✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Guide

503A vs 503B Compounding Pharmacies Explained

Released: Last reviewed:

Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing facilities.

Educational
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Overview

Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing facilities.

Related guides

Key facts, checked November 20, 2026

A 503A pharmacy is licensed by its state and compounds for an individual patient’s prescription. A 503B outsourcing facility registers with FDA, follows current good manufacturing practice and may compound in bulk. For GLP-1s, FDA’s 503B proposal (91 FR 23431) would keep tirzepatide, semaglutide and liraglutide off the 503B bulks list; comments closed July 30, 2026 and no final notice had appeared by November 20, 2026. Neither type of facility makes a compounded drug FDA-approved, and FDA’s 2026 warning letters objected to calling pharmacies “FDA-licensed.” See FDA’s page on unapproved GLP-1 drugs.